Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

about

Immune-mediated inflammatory diseases: progress in molecular pathogenesis and therapeutic strategies.Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines.

P2860

Q45886306-82CA0F47-1B31-4D40-909B-FEE5627626D8 Q54397994-EF408B69-7757-4B78-B21B-244BF08E6806

P2860

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

Item

http://www.wikidata.org/entity/Q38044757

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

@en

type

Item

label

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

@en

prefLabel

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

@en

P1476

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

@en

P2093

Troels Herlin

http://www.w3.org/2001/XMLSchema#string

P2860

Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolong

Gp130 and the interleukin-6 family of cytokines

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Anti-interleukin 6 receptor antibody treatment in rheumatic disease.

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.

Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

P304

517-525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECI.12.49

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230883993

http://www.w3.org/2001/XMLSchema#string

P698

22992145

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

about

P2860

P2860

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921